EU to tighten medical controls after breast implant scandal

A breast implant scandal affecting thousands of women this year damaged confidence and highlighted the need to tighten controls in Europe on everyday medical devices, the European Commission said Wednesday.

"We must do our best never to let this happen again," said EU Health and Consumer Policy Commissioner John Dalli, outlining plans for more transparent regulations "better adapted to scientific and ."

The new rules will cover every device, from the simplest plasters to life-support systems by way of in vitro diagnostic instruments, to ensure that they are correctly approved and then monitored in use.

Earlier this year, the French government recommended that faulty breast implants which were prone to rupture made by Poly Implant Prothese (PIP) should be removed.

More than 400,000 women around the world are believed to have received and many countries followed the French lead after the company was found to have used substandard, industrial-grade .

"Everybody was shocked by the scandal ... (which) damaged the confidence of patients, consumers and in the safety of the devices on which they rely every day," Dalli said.

Asked whether his regulations would have prevented the PIP scandal, he said they would "militate against such fraud" but the key issue was that once they were sold there had been no follow up to check the implants.

"What we want to emphasise is" the control of products once they are in use to check that they are made to the specifications laid down and approved, he said.

"If this had happened, the PIP would have been detected many, many years before."

The proposals mean medical devices will now have to undergo a "thorough assessment of safety and performance before they can be sold on the European market," with "control processes ... radically reinforced," a statement said.

The aim is to give healthcare professionals better information on the benefits and risks while manufacturers will benefit from clearer rules, with those not complying excluded from the market.

The market in the 27 EU states plus Norway and Switzerland was worth 95 billion euros in 2009, the statement said.

The proposals now go to the European Council and the European Parliament for approval.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Were clinical trial practices in East Germany questionable?

18 hours ago

Clinical trials carried out in the former East Germany in the second half of the 20th century were not always with the full knowledge or understanding of participants with some questionable practices taking place, according ...

Schumacher's doctor sees progress after injury

Oct 23, 2014

A French physician who treated Michael Schumacher for nearly six months after the Formula One champion struck his head in a ski accident says he is no longer in a coma and predicted a possible recovery within three years.

User comments